National Attorneys Launch Invokana Ketoacidosis Lawsuit Center
St. Louis, MO (PRWEB) July 07, 2015 -- Nationally-renowned attorneys in the realm of family and product liability law announce the launch of their new website, the Invokana Ketoacidosis Lawsuit Center. The website provides information on Invokana side effects and the Invokana FDA warning*, and serves as a resource for persons wishing to learn more about Invokana lawsuits for kidney problems, ketoacidosis, heart attack, and wrongful death allegations.
Invokana has been the subject of warnings from the FDA* and the Institute for Safe Medication Practices (ISMP)** this year. The FDA Safety Announcement, entitled, “FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood”, was released on May 15, 2015.* The FDA warns that Invokana and other sodium-glucose cotransporter-2 inhibiting drugs can result in an unsafe buildup of ketones, or acids, in the blood. This is a condition known as ketoacidosis, which the FDA refers to as “a serious condition” that “may require hospitalization”.* The symptoms of ketoacidosis include difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness.* According to the FDA warning, Invokana and other drugs in the SGLT2 class are approved for use to treat type 2 diabetes in adults.
The ISMP’s Quarter Watch journal featured a warning for a litany of other Invokana side effects, mostly related to renal toxicity or kidney problems.** These include kidney failure, kidney impairment, severe dehydration and fluid imbalance, kidney stones, urinary tract infections, and abnormal weight loss. The ISMP article reported that Invokana has more serious adverse event reports than 92% of other drugs the agency is currently monitoring. The piece raised the question of whether Invokana’s potential side effects outweigh its benefits:
“The unanswered question about canagliflozin (Invokana) is whether it has clinical benefits and whether those benefits outweigh its risks.”**
Invokana is also the subject of numerous FDA investigations which were launched when the drug was first approved in March of 2013, including a study of the drug’s cardiovascular outcomes, bone safety, and pediatric uses, according to an FDA press release.***
These Invokana attorneys are currently reviewing claims for kidney problems, ketoacidosis, and other serious health problems connected with Invokana. Invokana lawyers will provide a confidential case evaluation at no charge for persons who suffered kidney failure, blood acid problems, or another side effects while taking Invokana. Individuals who fit this description may contact a lawyer through the firm’s website for a no-obligation consultation on whether they have grounds for an Invokana lawsuit. The firm’s Invokana lawyers believe persons and the family members of persons who meet this description may be entitled to real compensation for the harm and damages they sustained while the makers and manufacturers of Invokana benefited from their business.
The Onder Law Firm welcomes Invokana lawsuit inquiries from law firms in regards to handling them or working as co-counsel.
About The Onder Law Firm
Onder, Shelton, O’Leary & Peterson, LLC is a St. Louis based personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The pharmaceutical and medical device litigators at The Onder Law Firm have represented thousands of Americans in lawsuits against multinational conglomerates from products liability for manufacture of defective or dangerous products to deceptive advertising practices. Other firms throughout the nation often seek its experience and expertise on complex litigation. It is also a recognized leader in products liability cases such as window blind cord strangulation. The Onder Law Firm offers information from Invokana attorneys at http://www.InvokanaKetoacidosisLawsuitCenter.com.
- fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf 5/15/15
**ismp.org/quarterwatch/pdfs/2014Q2.pdf “Unanswered Questions about Canagliflozin (INVOKANA)” 5/6/15
*** fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm “FDA approves Invokana to treat type 2 diabetes” 3/29/13
Michael Gudeman, Gudeman Group, +1 314-614-8709, [email protected]
Share this article